Targeted Therapies

  • Author: Gail Wilkes, RNC, ANP-BC, MS, AOCN® (More Info)
  • Section Editor: Marlene SanFilippo, MSN, ARNP, FNP-C, AOCNP®
  • Editors In Chief: Dawn Camp-Sorrell, MSN, FNP, AOCN®; Rebecca Hawkins, MSN, ANP, AOCN®, ACHPN
  • Last Reviewed: 5/26/17 (What's New)

Summary

  • Phosphatidylinositol 3-kinase (PI3K) is a new target in the treatment of B-lymphocyte malignancies
  • Idelalisib targets PI3K delta and is a first-in-class drug (Table 47)
  • Commonly occurring side effects include diarrhea, fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash

Action required